Specialty Pharmacy

A combination therapy may counter the resistance to human epidermal growth factor receptor 2 inhibitor neratinib in patients with breast, ovarian, lung, or other cancers.

Research may help to develop usable hematopoietic stem cells that could regrow a patient with leukemia’s blood system after chemotherapy and irradiation.

Specialty pharmacists are well positioned to manage the opioid epidemic because they are in regular contact with their patients who trust them.

Dupilumab has been granted priority review as an add-on maintenance treatment for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies.

Top news of the day from across the health care landscape.

Robust data show the efficacy of tenofovir disoproxil fumarate with emtricitabine for pre-exposure prophylaxis in all priority populations with a risk for HIV.

The study was the first to explore sociodemographic disparities in young adult patients with colorectal cancer.

Top news of the day from across the health care landscape.

Report demonstrates an increase in generic and new drug approvals, Orphan Drug designations, and an increase in the use of expediated approval programs.

Two large studies demonstrating patient-reported outcomes showed that quality of life was maintained longer with newer drug combinations compared with standard of care for the treatment of patients with a specific type of colorectal cancer (CRC) and unresectable hepatocellular carcinoma (HCC). The results were presented at the 2020 Gastrointestinal Cancers Symposium in San Francisco, California, from January 23-25.

A blood-based screening test using cell-free DNA may be able to identify cancer at earlier stages than what was previously possible, according to research to be presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 23 to 25 in San Francisco.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Tazemetostat blocks any activity of the EZH2 methyltransferase, which may help keep the cancer cells from further growth.

Pharmacies are using technology not only to offer safe filling, but generate greater engagement with their customer base.

Pfizer will become the first to launch 3 oncology monoclonal antibody biosimilar treatments to the US market.

The study was the first to examine proton pump inhibitors use in breast cancer survivors.

Top news of the day from across the health care landscape.

A proposed FDA guidance could significantly impact veterinary practices and their ability to compound medicines for animal patients, according to a national survey.1

Biosimilars, which at the most simplistic level can be thought of as a type of generic option for a biologic, offer an opportunity to help reduce total biologic drug spend.

Valoctocogene roxaparvovec (Valrox, BioMarin Pharmaceutical Inc) would be the first gene therapy in the United States for the most common form of hemophilia if approved by the FDA.1

The shift from fee-for-service to a value-based care payment model represents the growing understanding of the value of health care providers in improving overall patient outcomes.

The release of generic versions of brand name drugs for patients with multiple sclerosis had little overall effect on the price increase.

Top news of the day from across the health care landscape.

Margetuximab plus chemotherapy showed positive results in a second pre-specified interim overall survival analysis for the phase 3 SOPHIA study.

Top news of the day from across the health care landscape.

Antiretroviral therapy may not be entirely effective in restoring the immune protection resulting from viral infections or childhood vaccines received prior to becoming HIV-positive.

The report projects changes in upcoming health care markets, including kidney care, digital health, drug cost transparency, the loneliness epidemic, and the self-care market.

The findings support the inclusion of these patient populations in ICI-based clinical trials and treatment.

Safety net providers, which historically work in underserved communities, have successfully petitioned state legislatures to take action on 340B 2-tier pricing.